3/21
03:08 pm
glue
Rating for GLUE
Low
Report
Rating for GLUE
3/21
03:08 pm
glue
Rating for GLUE
Low
Report
Rating for GLUE
3/21
10:24 am
glue
Rating for GLUE
Medium
Report
Rating for GLUE
3/21
10:24 am
glue
Rating for GLUE
Medium
Report
Rating for GLUE
3/20
08:14 pm
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
High
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
3/20
08:14 pm
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
High
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.